相似文献
1
Taccalonolides: a microtubule stabilizer poses a new puzzle with old pieces.
Cell Cycle. 2011 Oct 1;10(19):3233-4. doi: 10.4161/cc.10.19.17126.
2
The taccalonolides and paclitaxel cause distinct effects on microtubule dynamics and aster formation.
Mol Cancer. 2014 Feb 28;13:41. doi: 10.1186/1476-4598-13-41.
3
Taccalonolides: Novel microtubule stabilizers with clinical potential.
Cancer Lett. 2010 May 1;291(1):14-9. doi: 10.1016/j.canlet.2009.09.020. Epub 2009 Oct 31.
4
Taccalonolide microtubule stabilizers.
Bioorg Med Chem. 2014 Sep 15;22(18):5091-6. doi: 10.1016/j.bmc.2014.01.012. Epub 2014 Jan 15.
5
Taccalonolide binding to tubulin imparts microtubule stability and potent in vivo activity.
Cancer Res. 2013 Nov 15;73(22):6780-92. doi: 10.1158/0008-5472.CAN-13-1346. Epub 2013 Sep 18.
6
Cellular studies reveal mechanistic differences between taccalonolide A and paclitaxel.
Cell Cycle. 2011 Jul 1;10(13):2162-71. doi: 10.4161/cc.10.13.16238.
7
Identification of C-6 as a New Site for Linker Conjugation to the Taccalonolide Microtubule Stabilizers.
J Nat Prod. 2019 Mar 22;82(3):583-588. doi: 10.1021/acs.jnatprod.8b01036. Epub 2019 Feb 25.
8
Chemically diverse microtubule stabilizing agents initiate distinct mitotic defects and dysregulated expression of key mitotic kinases.
Biochem Pharmacol. 2013 Apr 15;85(8):1104-14. doi: 10.1016/j.bcp.2013.01.030. Epub 2013 Feb 8.
9
Molecular dynamics simulation and free energy landscape methods in probing L215H, L217R and L225M βI-tubulin mutations causing paclitaxel resistance in cancer cells.
Biochem Biophys Res Commun. 2016 Aug 5;476(4):273-279. doi: 10.1016/j.bbrc.2016.05.112. Epub 2016 May 24.
10
Potent taccalonolides, AF and AJ, inform significant structure-activity relationships and tubulin as the binding site of these microtubule stabilizers.
J Am Chem Soc. 2011 Nov 30;133(47):19064-7. doi: 10.1021/ja209045k. Epub 2011 Nov 8.
引用本文的文献
1
Taccalonolide Microtubule Stabilizers.
Prog Chem Org Nat Prod. 2020;112:183-206. doi: 10.1007/978-3-030-52966-6_3.
2
Harnessing Plant Biodiversity for the Discovery of Novel Anticancer Drugs Targeting Microtubules.
Front Plant Sci. 2017 May 4;8:720. doi: 10.3389/fpls.2017.00720. eCollection 2017.
3
The taccalonolides and paclitaxel cause distinct effects on microtubule dynamics and aster formation.
Mol Cancer. 2014 Feb 28;13:41. doi: 10.1186/1476-4598-13-41.
4
Taccalonolide microtubule stabilizers.
Bioorg Med Chem. 2014 Sep 15;22(18):5091-6. doi: 10.1016/j.bmc.2014.01.012. Epub 2014 Jan 15.
本文引用的文献
1
Cellular studies reveal mechanistic differences between taccalonolide A and paclitaxel.
Cell Cycle. 2011 Jul 1;10(13):2162-71. doi: 10.4161/cc.10.13.16238.
2
Mitosis is not a key target of microtubule agents in patient tumors.
Nat Rev Clin Oncol. 2011 Feb 1;8(4):244-50. doi: 10.1038/nrclinonc.2010.228.
3
Microtubule interactions with chemically diverse stabilizing agents: thermodynamics of binding to the paclitaxel site predicts cytotoxicity.
Chem Biol. 2005 Dec;12(12):1269-79. doi: 10.1016/j.chembiol.2005.09.010.
4
Dolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel-Dreyer chromatography.
Eur J Biochem. 2003 Sep;270(18):3822-8. doi: 10.1046/j.1432-1033.2003.03776.x.
5
A steroid derivative with paclitaxel-like effects on tubulin polymerization.
Mol Pharmacol. 2000 Mar;57(3):568-75. doi: 10.1124/mol.57.3.568.
6
Sustained intracellular retention of dolastatin 10 causes its potent antimitotic activity.
Mol Pharmacol. 2000 Jan;57(1):180-7.
Zotero 插件